Simone A. Minnie, Olivia G. Waltner, Ping Zhang, Shuichiro Takahashi, Nicole S. Nemychenkov, Kathleen S. Ensbey, Christine R. Schmidt, Samuel R. W. Legg, Melissa Comstock, Julie R. Boiko, Ethan Nelson, Shruti S. Bhise, Alec B. Wilkens, Motoko Koyama, Madhav V. Dhodapkar, Marta Chesi, Stanley R. Riddell, Damian J. Green, Andrew Spencer, Scott N. Furlan, Geoffrey R. Hill
{"title":"TIM-3+ CD8 T cells with a terminally exhausted phenotype retain functional capacity in hematological malignancies","authors":"Simone A. Minnie, Olivia G. Waltner, Ping Zhang, Shuichiro Takahashi, Nicole S. Nemychenkov, Kathleen S. Ensbey, Christine R. Schmidt, Samuel R. W. Legg, Melissa Comstock, Julie R. Boiko, Ethan Nelson, Shruti S. Bhise, Alec B. Wilkens, Motoko Koyama, Madhav V. Dhodapkar, Marta Chesi, Stanley R. Riddell, Damian J. Green, Andrew Spencer, Scott N. Furlan, Geoffrey R. Hill","doi":"10.1126/sciimmunol.adg1094","DOIUrl":null,"url":null,"abstract":"<div >Chronic antigen stimulation is thought to generate dysfunctional CD8 T cells. Here, we identify a CD8 T cell subset in the bone marrow tumor microenvironment that, despite an apparent terminally exhausted phenotype (T<sub>PHEX</sub>), expressed granzymes, perforin, and IFN-γ. Concurrent gene expression and DNA accessibility revealed that genes encoding these functional proteins correlated with <i>BATF</i> expression and motif accessibility. IFN-γ<sup>+</sup> T<sub>PHEX</sub> effectively killed myeloma with comparable efficacy to transitory effectors, and disease progression correlated with numerical deficits in IFN-γ<sup>+</sup> T<sub>PHEX</sub>. We also observed IFN-γ<sup>+</sup> T<sub>PHEX</sub> within CD19-targeted chimeric antigen receptor T cells, which killed CD19<sup>+</sup> leukemia cells. An IFN-γ<sup>+</sup> T<sub>PHEX</sub> gene signature was recapitulated in T<sub>EX</sub> cells from human cancers, including myeloma and lymphoma. Here, we characterize a T<sub>EX</sub> subset in hematological malignancies that paradoxically retains function and is distinct from dysfunctional T<sub>EX</sub> found in chronic viral infections. Thus, IFN-γ<sup>+</sup> T<sub>PHEX</sub> represent a potential target for immunotherapy of blood cancers.</div>","PeriodicalId":21734,"journal":{"name":"Science Immunology","volume":null,"pages":null},"PeriodicalIF":17.6000,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Science Immunology","FirstCategoryId":"3","ListUrlMain":"https://www.science.org/doi/10.1126/sciimmunol.adg1094","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Chronic antigen stimulation is thought to generate dysfunctional CD8 T cells. Here, we identify a CD8 T cell subset in the bone marrow tumor microenvironment that, despite an apparent terminally exhausted phenotype (TPHEX), expressed granzymes, perforin, and IFN-γ. Concurrent gene expression and DNA accessibility revealed that genes encoding these functional proteins correlated with BATF expression and motif accessibility. IFN-γ+ TPHEX effectively killed myeloma with comparable efficacy to transitory effectors, and disease progression correlated with numerical deficits in IFN-γ+ TPHEX. We also observed IFN-γ+ TPHEX within CD19-targeted chimeric antigen receptor T cells, which killed CD19+ leukemia cells. An IFN-γ+ TPHEX gene signature was recapitulated in TEX cells from human cancers, including myeloma and lymphoma. Here, we characterize a TEX subset in hematological malignancies that paradoxically retains function and is distinct from dysfunctional TEX found in chronic viral infections. Thus, IFN-γ+ TPHEX represent a potential target for immunotherapy of blood cancers.
期刊介绍:
Science Immunology is a peer-reviewed journal that publishes original research articles in the field of immunology. The journal encourages the submission of research findings from all areas of immunology, including studies on innate and adaptive immunity, immune cell development and differentiation, immunogenomics, systems immunology, structural immunology, antigen presentation, immunometabolism, and mucosal immunology. Additionally, the journal covers research on immune contributions to health and disease, such as host defense, inflammation, cancer immunology, autoimmunity, allergy, transplantation, and immunodeficiency. Science Immunology maintains the same high-quality standard as other journals in the Science family and aims to facilitate understanding of the immune system by showcasing innovative advances in immunology research from all organisms and model systems, including humans.